The Efficacy and Safety of Intra-Arterial Administration of Rexmyelocel T to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus: Two Pivotal, Placebo Controlled, Double-Blind, Parallel-Group, Adaptive Trials
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Rexmyelocel T (Primary)
- Indications Peripheral ischaemia
- Focus Registrational; Therapeutic Use
- Sponsors Rexgenero
- 25 Jan 2018 According to a Rexgenero media release, the trial design including the patient population and primary endpoints, have been fully endorsed by the European Medicines Agency (EMA).
- 23 Nov 2017 This trial has been suspended in Spain.
- 22 Nov 2017 This trial has restarted in Austria.